The reiteration of an Overweight rating and maintenance of a $25 price target by a reputable analyst like Eric Joseph from JP Morgan is likely to instill confidence among investors and could positively influence TG Therapeutics' stock price in the short term. Analyst ratings, especially from well-regarded financial institutions, can significantly impact investor sentiment and stock prices.